Volume 19, Number 1—January 2013
CME ACTIVITY
Pneumocystis jirovecii Genotype Associated with Increased Death Rate of HIV-infected Patients with Pneumonia
Meja Rabodonirina, Laetitia Vaillant, Patrick Taffé, Aimable Nahimana, René-Pierre Gillibert, Philippe Vanhems, and Philippe M. Hauser
Table 2
Pneumocystis jiroveci SSCP genotype distribution according to clinical parameters of 112 cases of pneumonia in 110 HIV-positive patients from 5 university hospitals in Lyon, France*
| 1, n = 10 | 7, n = 9 | 10, n = 4 | Others, n = 36 | Co-infected, n = 53 | ||
|---|---|---|---|---|---|---|
| Age at PCP diagnosis, y | ||||||
|
1–40 |
8 | 5 | 2 | 22 | 28 | 0.89 |
|
41–60 |
2 | 4 | 2 | 13 | 22 | |
|
61–80 |
0
|
0
|
0
|
1
|
3
|
|
| Sex | ||||||
|
M |
3 | 1 | 1 | 6 | 6 | 0.44 |
|
F |
7
|
8
|
3
|
30
|
47
|
|
| Diagnosis year | ||||||
|
1993 |
1 | 0 | 0 | 2 | 5 | 0.90 |
|
1994 |
3 | 2 | 2 | 8 | 16 | |
|
1995 |
2 | 2 | 1 | 9 | 17 | |
|
1996 |
4
|
5
|
1
|
17
|
15
|
|
| CD4 cell count, median cells/μL† | ||||||
|
0–50 |
7 | 5 | 3 | 23 | 30 | 0.87 |
|
51–100 |
0 | 2 | 1 | 6 | 12 | |
|
>100 |
1
|
1
|
0
|
5
|
5
|
|
| First-line treatment | ||||||
|
SMX/TMP |
7 | 3 | 3 | 26 | 49 | 0.001 |
|
Pentamidine or atovaquone |
2 | 6 | 1 | 9 | 4 | |
|
Others |
1
|
0
|
0
|
1
|
0
|
|
| SMX/TMP allergy | ||||||
|
Yes |
0 | 2 | 0 | 3 | 2 | 0.27 |
|
No |
10
|
7
|
4
|
33
|
51
|
|
| Corticotherapy at PCP diagnosis | ||||||
|
Yes |
0 | 4 | 0 | 7 | 11 | 0.17 |
|
No |
10
|
5
|
4
|
29
|
42
|
|
| Mechanical ventilation at PCP diagnosis | ||||||
|
Yes |
0 | 2 | 0 | 2 | 10 | 0.19 |
|
No |
10
|
7
|
4
|
34
|
43
|
|
| Outcome within 1 month | ||||||
|
Favorable |
9 | 5 | 4 | 28 | 45 | 0.44 |
|
Death attributed to PCP |
1 | 4 | 0 | 6 | 7 | |
|
Death not attributed to PCP |
0 | 0 | 0 | 2 | 1 |
*Data derived from Fisher’s exact test. SSCP, single-strand conformation polymorphism; PCP, P. jirovecii pneumonia; SMX/TMP, sulfamethoxazole and trimethoprim.
†Data missing for 11 patients.
